Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model.
Specialized immune cells that infiltrate the tumor microenvironment regulate the growth and survival of neoplasia.  Malignant cells must elude or subvert anti-tumor immune responses in order to survive and flourish. Tumors take advantage of a number of different mechanisms of immune "escape," including the recruitment of tolerogenic DC, immunosuppressive regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSC) that inhibit cytotoxic anti-tumor responses. Conversely, anti-tumor effector immune cells can slow the growth and expansion of malignancies: immunostimulatory dendritic cells, natural killer cells which harbor innate anti-tumor immunity, and cytotoxic T cells all can participate in tumor suppression. The balance between pro- and anti-tumor leukocytes ultimately determines the behavior and fate of transformed cells; a multitude of human clinical studies have borne this out. Thus, detailed analysis of leukocyte subsets within the tumor microenvironment has become increasingly important. Here, we describe a method for analyzing infiltrating leukocyte subsets present in the tumor microenvironment in a mouse tumor model. Mouse B16 melanoma tumor cells were inoculated subcutaneously in C57BL/6 mice. At a specified time, tumors and surrounding skin were resected en bloc and processed into single cell suspensions, which were then stained for multi-color flow cytometry. Using a variety of leukocyte subset markers, we were able to compare the relative percentages of infiltrating leukocyte subsets between control and chemerin-expressing tumors. Investigators may use such a tool to study the immune presence in the tumor microenvironment and when combined with traditional caliper size measurements of tumor growth, will potentially allow them to elucidate the impact of changes in immune composition on tumor growth. Such a technique can be applied to any tumor model in which the tumor and its microenvironment can be resected and processed.
Division of Oncology, Department of Medicine, Washington University School of Medicine; rkpachynski@gmail.com.
Russell K
RK
Pachynski
Laboratory of Immunology and Vascular Biology, Department of Pathology, Stanford University School of Medicine.
Alexander
A
Scholz
Palo Alto Institute for Research and Education, Veterans Affairs Palo Alto Health Care System; Laboratory of Immunology and Vascular Biology, Department of Pathology, Stanford University School of Medicine.
Justin
J
Monnier
Laboratory of Immunology and Vascular Biology, Department of Pathology, Stanford University School of Medicine.
Eugene C
EC
Butcher
Palo Alto Institute for Research and Education, Veterans Affairs Palo Alto Health Care System.
Brian A
BA
Zabel
D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D005434:Flow Cytometry; D007694:Killer Cells, Natural / Q000276:immunology; D007962:Leukocytes / Q000276:immunology* / Q000473:pathology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology* / Q000473:pathology; D008546:Melanoma, Experimental / Q000276:immunology* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000473:pathology; D059016:Tumor Microenvironment